Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 8,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Atopic Dermatitis
Interventions: topical desonide hydrogel 0.05%; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 3 Months and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Physical Activity
Interventions: Group A, Group B; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Flagstaff, Arizona • Columbia, Missouri

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: centanafadine capsule, placebo capsule; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Migraine Prophylaxis
Interventions: Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 35
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more

Conditions: Wet Age Related Macular Degeneration, Wet AMD
Interventions: NT-101 Low Dose, NT-101 High Dose; Drug
Lead sponsor: NexThera Co., Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more

Conditions: Healthy Volunteers, Pneumococcal Disease
Interventions: ASP3772, PCV13; Biological
Lead sponsor: Affinivax, Inc.; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 17
States / cities: Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more

Conditions: Alzheimer Disease
Interventions: florbetapir F 18; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Jenkintown, Pennsylvania

Conditions: Asthma
Interventions: arformoterol, levalbuterol; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 14
States / cities: Beverly Hills, California • Orange, California • Savannah, Georgia + 10 more

Conditions: Acute Myeloid Leukemia, Leukemia, Myeloid
Interventions: Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index, Blood Test/Blood Draw, Hand Grip Strength Test; Device · Other · Diagnostic Test
Lead sponsor: University of Chicago; Other
Eligibility: 60 Years and older
Enrollment: 239 participants
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Friedreich Ataxia
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Not listed
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more

Conditions: Meningococcal Vaccine
Interventions: MenABCWY, Saline, rLP2086, MenACWY-CRM; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more

Conditions: Reproductive Physiological Processes, Pediatrics, Adolescent Health, Adolescent Development
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 8 Years to 65 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Aging
Interventions: Mobile Service Robot, Survey; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vestibulopathy
Interventions: electrical vestibular stimulation (EVS), Sham Comparator; Device
Lead sponsor: Neursantys Inc; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cupertino, California • Menlo Park, California

Conditions: Perennial Allergic Rhinitis
Interventions: Placebo Nasal Aerosol, Prednisone capsules, Placebo Prednisone Capsules, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: North Dartmouth, Massachusetts • New Braunfels, Texas • San Antonio, Texas

Conditions: Tracheal Intubation
Interventions: Fiberoptic Intubation through the nasal route, Fiberoptic intubation through the oral route; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Day to 2 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Anaheim, California • Fountain Valley, California • Los Angeles, California + 21 more

Conditions: Eye Diseases
Interventions: Calcium alpha-ketoglutarate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Gonorrhea, Chlamydia
Interventions: Targeted STI Screening, Universally Offered STI Screening; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 21 Years
Enrollment: 98,413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 5
States / cities: Aurora, Colorado • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: MVA-BN-RSV vaccine, Tris Buffered Saline (TBS); Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 60 Years and older
Enrollment: 20,419 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 105
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab (Lucentis), 0.5mg ranibizumab; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 55 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pediatric Obstructive Sleep Apnea, Down Syndrome (DS)
Interventions: Hypoglossal Nerve Stimulation; Device
Lead sponsor: Inspire Medical Systems, Inc.; Industry
Eligibility: 13 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Phoenix, Arizona • Orange, California • Tampa, Florida + 3 more

Conditions: Stroke, Hemiplegia, Healthy
Interventions: Rehab InterCap system and 3D Kinect; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Erythropoietic Protoporphyria
Interventions: Colestipol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 22 Years to 60 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis

Physical Activity and Dietary Behaviors of Adults 18 to 80 Years of Age

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

A Study of 18F-AV-45 in Healthy Volunteers

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia

A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Reproductive Axis Maturation in the Early Post-Menarchal Years

Affordable Mobile Robots for the Elderly

Therapeutic Effects of Electrical Vestibular Stimulation (EVS) on Balance and Gait

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

A Comparison of Nasal Versus Oral Fiberoptic Intubation in Children

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Effect of Nutritional Supplement Alpha-ketoglutarate for Age-related Ocular Disease

Adolescent Sexually Transmitted Infection Screening in the Emergency Department

MVA-BN-RSV Vaccine Trial

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Pediatric Down Syndrome Post-Approval Study

Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions

Sorbent Therapy of the Cutaneous Porphyrias